Show simple item record

dc.contributor.authorLoureiro, Anaen
dc.contributor.authorLopes Bernardes, Goncaloen
dc.contributor.authorShimanovich, Ulyanaen
dc.contributor.authorSárria, Marisa Pen
dc.contributor.authorNogueira, Eugéniaen
dc.contributor.authorPreto, Anaen
dc.contributor.authorGomes, Andreia Cen
dc.contributor.authorCavaco-Paulo, Arturen
dc.date.accessioned2015-05-21T13:02:42Z
dc.date.available2015-05-21T13:02:42Z
dc.date.issued2015-03-16en
dc.identifier.citationNanomedicine: Nanotechnology, Biology and Medicine Volume 11, Issue 5, July 2015, Pages 1077–1083. doi:10.1016/j.nano.2015.02.022en
dc.identifier.issn1549-9634
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/247903
dc.description.abstractFolic Acid (FA)-tagged protein nanoemulsions were found to be preferentially internalized on B-cell lymphoma cell line (A20 cell line), which, for the first time, are reported to express folate receptor (FR)-alpha. Carbon monoxide releasing molecule-2 (CORM-2) was incorporated in the oil phase of the initial formulation. FA-functionalized nanoemulsions loaded with CORM-2 exhibited a considerable antitumor effect and an increased survival of BALB/c mice bearing subcutaneous A20 lymphoma tumors. The developed nanoemulsions also demonstrated to be well tolerated by these immunocompetent mice. Thus, the results obtained in this study demonstrate that FA-tagged protein nanoemulsions can be successfully used in cancer therapy, with the important ability to delivery drugs intracellularly.
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivs 2.0 UK: England & Wales*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.0/uk/*
dc.subjectProtein nanoemulsionsen
dc.subjectFolic aciden
dc.subjectCORM-2en
dc.subjectSpecific uptakeen
dc.subjectTargeted drug deliveryen
dc.titleFolic Acid-Tagged Protein Nanoemulsions Loaded with CORM-2 Enhance the Survival of Mice Bearing Subcutaneous A20 Lymphoma Tumorsen
dc.typeArticle
dc.description.versionThis is the author accepted manuscript. The final version is avilable via Elsevier at http://www.sciencedirect.com/science/article/pii/S1549963415000726.en
prism.endingPage1083
prism.publicationDate2015en
prism.publicationNameNanomedicine: Nanotechnology, Biology, and Medicineen
prism.startingPage1077
prism.volume11en
dcterms.dateAccepted2015-02-24en
rioxxterms.versionofrecord10.1016/j.nano.2015.02.022en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2015-03-16en
dc.contributor.orcidLopes Bernardes, Goncalo [0000-0001-6594-8917]
dc.identifier.eissn1549-9642
rioxxterms.typeJournal Article/Reviewen
rioxxterms.freetoread.startdate2016-03-16


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivs 2.0 UK: England & Wales